A recent study indicates that individuals who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional lifestyle regimens.
Research printed in a leading medical journal demonstrates that while obese individuals frequently drop about a fifth of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"People purchasing such medications need to be aware of the danger of quick rebound weight gain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight in about one and a half years.
Analyzing Treatments
The study, which reviewed dozens of trials involving thousands of patients, contrasted the results of the injectable medications with other pills.
Researchers emphasize that individuals who lose weight through dieting typically experience a slower weight regain—around 100 grams monthly—post-intervention.
Understanding the Fast Regain
Doctors believe the mode of action of the injections accounts for the amplified regain.
The injections imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making overeating much more probable."
A Lifelong Condition?
The NHS advise the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts say that, considering the high risk of relapse, the treatment is often ongoing.
This view is supported by drug manufacturers, who note that the results "underscore the persistent nature of excess weight," akin to managing conditions like diabetes.
Patient Accounts
Users who have come off the medication explain a sudden resurgence of appetite.
"I experienced a trigger that goes on and you're instantly ravenous," described a patient.
This difficulty is exacerbated if individuals have not established sustainable lifestyle or habit modifications during treatment.
Widespread Adoption
Survey data suggest that millions of people in the UK have used these injections in the past year, with interest being substantial.
- Adoption is higher among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and lasting health benefits hinges on combined lifestyle support.
